BriaCell Therapeutics Corp News - BCT

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 01, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

NEW YORK and VANCOUVER, British Columbia, Aug. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

NEW YORK and VANCOUVER, British Columbia and LOS ANGELES, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BriaCell...

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

NEW YORK and VANCOUVER, British Columbia, July 14, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell to Present at Three Upcoming Investor Conferences

BERKELEY, Calif. and VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell is expanding its breast cancer platform technology into other cancers including prostate, melanoma...

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

BERKELEY, Calif. and VANCOUVER, British Columbia, June 10, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

BERKELEY, Calif. and VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

BERKELEY, Calif. and VANCOUVER, British Columbia, June 07, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

L'OCRCVM permet la reprise de la négociation - BCT

L'OCRCVM permet la reprise de la négociation - BCT Canada NewsWire VANCOUVER, BC, le 3 juin 2021 VANCOUVER, BC, le 3 juin 2021 /CNW/...

IIROC Trading Resumption - BCT

IIROC Trading Resumption - BCT Canada NewsWire VANCOUVER, BC, June 3, 2021 VANCOUVER, BC, June 3, 2021 /CNW/ - Trading resumes in: Company:...

BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement

BERKELEY, Calif. and VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics...

IIROC Trading Halt - BCT

IIROC Trading Halt - BCT Canada NewsWire VANCOUVER, BC, June 3, 2021 VANCOUVER, BC, June 3, 2021 /CNW/ - The following issues have been halted by...

Suspension de la négociation par l'OCRCVM - BCT

Suspension de la négociation par l'OCRCVM - BCT Canada NewsWire VANCOUVER, BC, le 3 juin 2021 VANCOUVER, BC, le 3 juin 2021 /CNW/...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

BriaCell Therapeutics Corp (BCT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BCT News

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

BriaCell to Present at Three Upcoming Investor Conferences

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

L'OCRCVM permet la reprise de la négociation - BCT

IIROC Trading Resumption - BCT

BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement

IIROC Trading Halt - BCT

Suspension de la négociation par l'OCRCVM - BCT

BCT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

BriaCell Therapeutics Corp (BCT) News

BriaCell Therapeutics Corp (BCT)

Empower your portfolio: Real-time discussions and actionable trading ideas.

BCT News

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

BriaCell to Present at Three Upcoming Investor Conferences

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

L'OCRCVM permet la reprise de la négociation - BCT

IIROC Trading Resumption - BCT

BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement

IIROC Trading Halt - BCT

Suspension de la négociation par l'OCRCVM - BCT

BCT Discussion

Your Recent History